Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III global master protocol of BNT327 with chemotherapy and other investigational agents for first-line non-small cell lung cancer
CTR20252064Phase 2Active
- Sponsor
- Biotheus
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig in non-small cell lung cancer (NSCLC), sponsored by Biotheus. Started Aug 2025; status: active.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20252064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252064.